This study aims to understand differences in access to diagnosis and treatment for people with multiple sclerosis (MS) receiving care in Libya. The study uses data from the Libyan Multiple Sclerosis Registry, which collects clinical and treatment information from patients at two tertiary neurology centres. The main focus is to examine how long it takes for patients to receive an MS diagnosis, who has access to high-efficacy disease-modifying therapies, and how these factors relate to disability levels. The results will help identify gaps in MS care within a conflict-affected health system and guide improvements in services for patients in Libya.
Study Type
OBSERVATIONAL
Enrollment
369
This is an observational study. No medications are assigned, administered, or modified by the study team. Disease-modifying therapies (DMTs) are recorded only as exposure variables based on routine clinical care. All drugs listed in this record are prescribed independently by treating neurologists as part of standard care, and the study does not influence treatment decisions in any way.
Tripoli University Hospital
Zintan, Libya
Moderate-to-Severe Disability (EDSS ≥3.0)
Disability measured using the Expanded Disability Status Scale (EDSS). Moderate-to-severe disability is defined as EDSS ≥3.0, assessed by trained neurologists using standardised procedures.
Time frame: At registry entry
Moderate-to-Severe Disability (EDSS ≥3.0)
Time frame: At registry entry
EDSS Ordinal Disability Categories
Disability severity categorised using the Expanded Disability Status Scale (EDSS) into three groups: 0-2.5 (mild), 3.0-5.5 (moderate), and ≥6.0 (severe). EDSS scores are assessed by trained neurologists at the time of registry entry.
Time frame: At registry entry
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.